212 related articles for article (PubMed ID: 35833726)
1. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
[TBL] [Abstract][Full Text] [Related]
2. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
3. Targeting Son of Sevenless 1: The pacemaker of KRAS.
Kessler D; Gerlach D; Kraut N; McConnell DB
Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
[TBL] [Abstract][Full Text] [Related]
4. The KRAS
Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
[TBL] [Abstract][Full Text] [Related]
5. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
[TBL] [Abstract][Full Text] [Related]
6. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
Zhang S; Zhang Y; Chen X; Xu J; Fang H; Li Y; Liu Y; He H
J Med Chem; 2022 Dec; 65(23):15856-15877. PubMed ID: 36384290
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
He H; Zhang Y; Xu J; Li Y; Fang H; Liu Y; Zhang S
J Med Chem; 2022 Oct; 65(19):13158-13171. PubMed ID: 36173339
[TBL] [Abstract][Full Text] [Related]
9. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
10. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
11. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
[TBL] [Abstract][Full Text] [Related]
12. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
[No Abstract] [Full Text] [Related]
13. Affinity Measurement of Non-covalent Interactions of the Covalent KRAS G12C GDP Inhibitor MRTX849 to RAS Isoforms Using Surface Plasmon Resonance.
Alexander P; Stephen AG
Methods Mol Biol; 2024; 2797():103-114. PubMed ID: 38570455
[TBL] [Abstract][Full Text] [Related]
14. 143D, a novel selective KRAS
Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
[TBL] [Abstract][Full Text] [Related]
15. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
16. D-1553: A novel KRAS
Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
[TBL] [Abstract][Full Text] [Related]
17. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Smith CR; Chen D; Christensen JG; Coulombe R; Féthière J; Gunn RJ; Hollander J; Jones B; Ketcham JM; Khare S; Kuehler J; Lawson JD; Marx MA; Olson P; Pearson KE; Ren C; Tsagris D; Ulaganathan T; Van't Veer I; Wang X; Ivetac A
J Med Chem; 2024 Jan; 67(1):774-781. PubMed ID: 38156904
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
[TBL] [Abstract][Full Text] [Related]
20. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
